Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis (Q33862073)

29 July 2017

8 references

13 March 2019

23 March 2019

21 March 2019

22 April 2019

22 June 2019

11 September 2020

28 January 2021

6 February 2021

Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis (English)

1 reference

29 July 2017

Pseudomonas aeruginosa

0 references

6 references

13 March 2019

23 March 2019

21 March 2019

22 April 2019

22 June 2019

11 September 2020

6 references

13 March 2019

23 March 2019

21 March 2019

22 April 2019

22 June 2019

11 September 2020

1 reference

11 September 2020

1 reference

6 February 2021

1

Niels Høiby

0 references

language of work or name

English

0 references

publication date

4 April 2011

9 references

29 July 2017

13 March 2019

23 March 2019

21 March 2019

22 April 2019

22 June 2019

11 September 2020

28 January 2021

6 February 2021

9 references

29 July 2017

13 March 2019

23 March 2019

21 March 2019

22 April 2019

22 June 2019

11 September 2020

28 January 2021

6 February 2021

9

1 reference

29 July 2017

32

1 reference

Creative Commons Attribution 2.0 Generic

29 July 2017

8 references

13 March 2019

23 March 2019

21 March 2019

22 April 2019

22 June 2019

11 September 2020

28 January 2021

on focus list of Wikimedia project

6 February 2021

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/1741-7015-9-32

0 references

cites work

Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Pseudomonas aeruginosa biofilms in cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

The role of azithromycin in patients with cystic fibrosis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Antibiotic resistance of bacterial biofilms

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Extracellular DNA and F-actin as targets in antibiofilm cystic fibrosis therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Aerosol antibiotics in cystic fibrosis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Clinical trials in cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Eradication of early Pseudomonas aeruginosa infection

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Early intervention and prevention of lung disease in cystic fibrosis: a European consensus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

New concepts of the pathogenesis of cystic fibrosis lung disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Early infection and progression of cystic fibrosis lung disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Lower airway inflammation in infants with cystic fibrosis detected by newborn screening.

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-32

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-32

Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-32

Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-32

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-32

Pharmacokinetics of inhaled colistin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-32

Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-32

Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-32

Cost of care and clinical condition in paediatric cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-32

Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-32

Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-32

Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis--a pilot randomized controlled trial.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3087692

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it

29 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-32

Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-32

Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study

21 January 2018

1 reference

12 December 2020

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

12 December 2020

Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

1 reference

12 December 2020

Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis

1 reference

12 December 2020

Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis

1 reference

12 December 2020

Identifiers

DOI

10.1186/1741-7015-9-32

1 reference

PubMed ID

21463524

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference

PubMed ID

21463524